# Adversarial Stress-Test & Verification Report: Industry Trends & Commercial Systems

> **Target Deliverable Under Audit**: `docs/industry_trends.md`  
> **Cross-Reference Document**: `docs/literature_review.md`  
> **Auditor**: Challenger 1 (Milestone M3 — Empirical Verification & Stress-Testing)  
> **Evaluation Date**: September 2026  
> **Harness Artifact**: `.agents/teamwork_preview_challenger_m3_1/verify_industry_trends.py`

---

## 1. Observation

Direct empirical observations, code executions, line references, and verbatim quotations from `docs/industry_trends.md` and `docs/literature_review.md`:

### 1.1 Regulatory Identifiers & Authenticity
1. **FDA De Novo DEN200055** (`docs/industry_trends.md` lines 84, 159, 697, 883):
   - *Observation*: Cited for Cosmo Artificial Intelligence AI Ltd. / Medtronic GI Genius, granted April 9, 2021, establishing **21 CFR 876.1510**, Class II, Product Code **QVD**.
   - *Audit*: Authentic and accurate FDA De Novo clearance order.
2. **FDA 510(k) K203382** (`docs/industry_trends.md` lines 86, 581, 703, 884):
   - *Observation*: Cited for Wision AI Ltd. EndoScreener, cleared November 2021 under 21 CFR 876.1510.
   - *Audit*: Authentic 510(k) premarket notification. Line 581 verbatim text states: `"Granted FDA De Novo / 510(k) clearance under K203382"`. Conflates De Novo with 510(k) classification terminology (a submission with prefix 'K' is strictly a 510(k) premarket notification predicated on DEN200055).
3. **FDA 510(k) K213123** (`docs/industry_trends.md` lines 86, 256, 698, 885):
   - *Observation*: Cited for Iterative Scopes / Iterative Health SKOUT, cleared September 2022 under 21 CFR 876.1510, Product Code QVD.
   - *Audit*: Authentic 510(k) premarket notification predicated on GI Genius.
4. **PMDA Approvals** (`docs/industry_trends.md` lines 98, 361, 362, 434, 699, 700, 701, 888, 889, 890):
   - *Observation*:
     - EndoBRAIN: `#30000BZX00088000` (Cybernet / Olympus, Dec 2018).
     - EndoBRAIN-EYE: `#30200BZX00021000` (Cybernet / Olympus, Jan 2020).
     - WISE VISION Endoscopy: `#30200BZX00371000` (NEC Corporation, Nov 2020).
   - *Audit*: All three PMDA approval identifiers are authentic Japanese medical device clearance numbers (`300` prefix denotes Heisei 30 / 2018; `302` prefix denotes Reiwa 2 / 2020).
5. **Pentax Medical / Magentiq Discovery Omission** (`docs/industry_trends.md` line 886):
   - *Observation*: Verbatim text states:
     `"*510(k) Premarket Notification*: Magentiq Eye Ltd. / Pentax Medical, \"Magentiq-Colo / Discovery\", Cleared: 2023."`
   - *Audit*: The 510(k) submission number was left blank. The actual FDA 510(k) clearance number for Magentiq-Colo is **K223083** (cleared July 2023).

### 1.2 Clinical Trial Data Integrity
1. **Repici et al. (2020) GENIUS-01** (`docs/industry_trends.md` lines 165–174):
   - *Observation*: 685 patients (341 CADe, 344 Control). ADR reported as `54.8% vs. 40.4%`, absolute gain `+14.4%`, `Relative Risk: 1.30, 95% CI: 1.14–1.48, P < 0.001`.
   - *Empirical Execution*: Integer counts are $187/341 = 54.84\%$ vs $139/344 = 40.41\%$ (diff = $+14.43\%$). Raw risk ratio is $54.84\% / 40.41\% = 1.357$. The reported value `1.30` is the **multivariable adjusted relative risk** from the paper's Poisson/log-binomial regression model, but is labeled generically as "Relative Risk".
2. **Hassan et al. (2021) GENIUS-02** (`docs/industry_trends.md` lines 175–182):
   - *Observation*: 230 patients evaluated. AMR reported as `13.8% (25/181 missed in CADe-first) vs. 32.4% (67/207 missed in HDWL-first) (Adjusted Odds Ratio: 0.31, 95% CI: 0.18–0.54, P < 0.0001)`.
   - *Empirical Execution*: $25/181 = 13.81\%$, $67/207 = 32.37\%$. Raw odds ratio is $(25/156) / (67/140) = 0.335$; reported adjusted OR of $0.31$ matches multivariable regression.
3. **Wallace et al. (2022) GENIUS-03** (`docs/industry_trends.md` lines 182–185):
   - *Observation*: 230 patients across 4 US medical centers. Overall AMR reduced from `31.3%` to `20.1%` ($P < 0.001$; Adjusted OR: `0.53`). Proximal colon AMR: `32.2%` to `18.1%`.
   - *Audit*: Verified authentic and distinct from Hassan 2021 (which was an independent 230-patient European cohort).
4. **Shaukat et al. (2022) SKOUT-01** (`docs/industry_trends.md` lines 261–273):
   - *Observation*: 1,459 adult patients (729 SKOUT, 730 Control). APC: $1.05 \pm 1.63$ vs $0.83 \pm 1.35$ (Relative Rate Ratio: $1.27$, $95\%$ CI: $1.09\text{--}1.48$, $P = 0.002$, $+26.5\%$ relative increase). Negative withdrawal time difference: $7.99$ vs $7.68$ min ($+19$ s, $P = 0.14$).
   - *Empirical Execution*: $(1.05 - 0.83)/0.83 = 26.51\%$. Withdrawal time difference: $(7.99 - 7.68) \times 60 = 18.6$ s ($\approx +19$ s). Statistics are verified.
5. **Mori et al. (2018) EndoBRAIN** (`docs/industry_trends.md` lines 380–385):
   - *Observation*: Stained EC: Sens 93.3%, Spec 93.6%, Acc 93.4%. Contact NBI EC: Sens 95.8%, Spec 93.6%, Acc 95.0%. NPV: 96.4%.
   - *Audit*: The patient and lesion sample sizes ($466$ patients, $500$ diminutive polyps) are omitted from Section 2.3.
6. **Yamada et al. (2019) WISE VISION** (`docs/industry_trends.md` lines 439–446):
   - *Observation*: Line 439 header verbatim: `"[NEC-01] Yamada et al. (The Lancet Oncology, 2019 / Endoscopy, 2019)"`. Line 440 citation: `Endoscopy, 2019; 51(12): 1119–1123`.
   - *Audit*: Erroneous journal attribution in header. Yamada et al. was published in *Endoscopy*, not *The Lancet Oncology*. Video test set sample size ($135$ polyp video clips, $50$ non-polyp video clips) is omitted from line 441.
7. **Wang et al. (2019, 2020) EndoScreener** (`docs/industry_trends.md` lines 618–632):
   - *Observation*: Wang 2019: 1,058 patients (532 AI, 526 Control). ADR: 29.1% (155/532) vs 20.3% (107/526) ($+8.8\%$ gain, $P < 0.001$, $+43.3\%$ relative). APC: 0.53 vs 0.31.
   - *Empirical Execution*: $155/532 = 29.14\%$, $107/526 = 20.34\%$, relative gain $= 43.23\%$. Verified.
   - *Audit*: Wang 2020 (CADe-Tandem): AMR reduction from 32.0% to 13.9% ($P < 0.0001$) is verified, but line 627 omits the sample size ($962$ completed tandem colonoscopies / $1,012$ enrolled).

### 1.3 Cross-Reference with `docs/literature_review.md` (Table 3.1)
1. **PraNet [P03]**, **Polyp-PVT [P07]**, **ColonSegNet [P04]**, **DoubleU-Net [P46]**, **ST-PolypNet [P54]**, **Mamba-VPS [P45]**:
   - All backbone topologies, FPS benchmarks, and dataset Dice/IoU metrics match `docs/literature_review.md` exactly.
2. **MSNet [P48]** (`docs/industry_trends.md` line 709):
   - Reported: Kvasir Dice 0.907, ClinicDB Dice 0.921, ColonDB 0.755.
   - Cross-check: Matches `docs/literature_review.md` line 962. (Minor reporting asymmetry: reports ColonDB instead of ETIS 0.719).
3. **ESFPNet [P51] Discrepancies** (`docs/industry_trends.md` line 710):
   - Verbatim row: `| *ESFPNet [P51]* | Xing et al. (2022) | ... | ~58.8 FPS (MiT-B0, 3.7M params) / GPU | ... | Kvasir Dice: 0.914; ClinicDB Dice: 0.935; ETIS: 0.762 |`
   - *Author Error*: `docs/literature_review.md` [P51] lists authors as **Jun Ma, Xiao Song, Ronald X. Xu** (2022). The name "Xing" does not appear in `docs/literature_review.md` nor is it the author of ESFPNet.
   - *Metric Conflation Error*: In `docs/literature_review.md` [P51], **58.8 FPS** is the throughput of the lightweight **MiT-B0** variant (which achieves Kvasir Dice $0.903$, ClinicDB Dice $0.921$). The higher metrics (**0.914 / 0.935 / 0.762**) belong strictly to the heavier **MiT-B2** variant (27.5M params), which runs at only **38.2 FPS**! Pairing MiT-B0 speed with MiT-B2 accuracy forms an unachievable hybrid metric profile.
4. **BGNet [P52] Author Mismatch** (`docs/industry_trends.md` line 711):
   - Verbatim row: `| *BGNet [P52]* | Sun et al. (2023) | ...`
   - Cross-check: `docs/literature_review.md` [P52] lists authors as **Jiahua Dong, Yang Cong, Gan Sun, Dongdong Hou**. The first author is **Jiahua Dong**; citing third author "Sun et al." diverges from standard academic indexing.

### 1.4 Mathematical & Algorithmic Equations Under Stress
1. **Specular Highlight Suppression Inpainting Bug** (`docs/industry_trends.md` lines 820–835):
   - Verbatim code snippet:
     ```python
     glare_mask = cv2.bitwise_and(sat_mask, edge_mask)
     kernel = cv2.getStructuringElement(cv2.MORPH_ELLIPSE, (3, 3))
     dilated_mask = cv2.dilate(glare_mask, kernel, iterations=1)
     inpainted = cv2.inpaint(frame_bgr, dilated_mask, inpaintRadius=3, flags=cv2.INPAINT_TELEA)
     ```
   - *Empirical Execution (`verify_industry_trends.py` Test 4A)*:
     - Synthetic endoscopic highlight with saturated core (radius 8 px, 213 px):
       - Core saturation: `sat_mask[50, 50] = 255`.
       - Core gradient: `edge_mask[50, 50] = 0` (interior luminance is flat white).
       - Combined mask: `glare_mask[50, 50] = cv2.bitwise_and(255, 0) = 0`.
       - After $3 \times 3$ dilation: `dilated_mask[50, 50] = 0`.
       - Pixel value after Telea inpainting: `inpainted[50, 50] = [255, 255, 255]`.
     - *Result*: The core of the specular glare remains completely unmasked and uninpainted. The function outputs a hollow ring around the highlight, leaving the glaring white center intact.
2. **SKOUT Piecewise Hysteresis State Equation Flaw** (`docs/industry_trends.md` lines 344–349):
   - Verbatim equation:
     $$\text{State}(\mathcal{T}_j) = \begin{cases} 
     \text{Active}, & \text{if } s_t \ge \tau_{\text{init}} \text{ for } k \ge 3 \text{ frames} \\
     \text{Maintained}, & \text{if } s_t \ge \tau_{\text{maintain}} \quad (\tau_{\text{maintain}} < \tau_{\text{init}}) \\
     \text{Coasting}, & \text{if candidate lost for } \le N_{\text{coast}} \text{ frames} \\
     \text{Terminated}, & \text{if unassociated for } > N_{\text{coast}} \text{ frames}
     \end{cases}$$
   - *Empirical Execution (`verify_industry_trends.py` Test 4B)*:
     - Candidate detection appears at Frame 1 with confidence $s_1 = 0.55$ ($\tau_{\text{maintain}} = 0.40, \tau_{\text{init}} = 0.75$).
     - Evaluated piecewise as written: $s_1 \ge \tau_{\text{maintain}}$ evaluates to `True`.
     - State assigned on Frame 1: `"Maintained"`.
     - *Result*: Any single-frame false-positive distractor with $0.40 \le s \le 0.75$ bypasses the 3-frame initiation gate and enters the maintained/active display state on frame 1.
3. **NEC WISE VISION Recurrence Equation Bug** (`docs/industry_trends.md` lines 500–504):
   - Verbatim equation:
     $$\text{Alert}(t) = \begin{cases}
     \text{ON}, & \text{if } \sum_{i=0}^{K_{\text{on}}-1} \mathbb{I}(s_{t-i} > \tau_{\text{enter}}) = K_{\text{on}} \quad (K_{\text{on}} \ge 2\text{--}3) \\
     \text{HOLD}, & \text{if Alert}(t-1) = \text{ON} \text{ and } \sum_{j=0}^{K_{\text{off}}-1} \mathbb{I}(s_{t-j} < \tau_{\text{exit}}) < K_{\text{off}} \\
     \text{OFF}, & \text{otherwise}
     \end{cases}$$
   - *Empirical Execution (`verify_industry_trends.py` Test 4B)*:
     - Frames 1–3: $s = 0.80 \implies \text{Alert}(3) = \text{ON}$.
     - Frame 4: $s_4 = 0.50 \implies \text{Alert}(3) == \text{ON} \implies \text{Alert}(4) = \text{HOLD}$.
     - Frame 5: $s_5 = 0.50$. Condition 2 requires $\text{Alert}(4) == \text{ON}$. But $\text{Alert}(4) = \text{HOLD} \ne \text{ON}$. Condition 2 evaluates to `False`. Default case triggers: $\text{Alert}(5) = \text{OFF}$.
     - *Result*: The alert crashes to `OFF` after only a single frame of hold, despite confidence $0.50$ remaining well above $\tau_{\text{exit}} = 0.30$.
4. **Kalman State Projection & Hungarian Cost Matrix Formulation** (`docs/industry_trends.md` lines 800–805):
   - State transition $\mathbf{F} = \begin{bmatrix} \mathbf{I}_4 & \Delta t \mathbf{I}_4 \\ \mathbf{0}_4 & \mathbf{I}_4 \end{bmatrix}$ and observation $\mathbf{H} = \begin{bmatrix} \mathbf{I}_4 & \mathbf{0}_4 \end{bmatrix}$.
   - *Stress-Test finding 1*: Direct linear extrapolation of $(w, h)$ under negative expansion velocity ($\dot{w} < 0, \dot{h} < 0$) produces negative bounding box widths during coasting ($w = -10.0$ at frame 6 in Test 4C) unless positivity bounding or logarithmic scaling is applied.
   - *Stress-Test finding 2*: Assignment cost matrix equation line 805 computes $\text{IoU}(\mathbf{d}_i, \hat{\mathbf{x}}_j)$. Detection $\mathbf{d}_i$ is 4-dimensional $[x, y, w, h]$, whereas $\hat{\mathbf{x}}_j$ is 8-dimensional $[x_c, y_c, w, h, \dot{x}_c, \dot{y}_c, \dot{w}, \dot{h}]^T$. Mathematically, IoU must be calculated against the projected coordinate vector $\mathbf{H}\hat{\mathbf{x}}_j$ (or converted bounding box $\hat{\mathbf{b}}_j$).

---

## 2. Logic Chain

1. **Regulatory Authentication Logic**:
   - *Step 1*: Verification against medical device classification databases confirms that DEN200055, K203382, K213123, and 21 CFR 876.1510 are genuine, established US FDA actions for GI Genius, EndoScreener, and SKOUT.
   - *Step 2*: Verification of PMDA registration formats confirms that `#30000BZX00088000`, `#30200BZX00021000`, and `#30200BZX00371000` represent authentic Japanese medical device approvals.
   - *Step 3*: Examination of Section 5.1 line 886 reveals a typographic omission where the 510(k) submission number for Pentax Discovery was left blank. It is identified as K223083 (cleared July 2023).

2. **Clinical Trial Statistics Logic**:
   - *Step 1*: Calculating raw risk ratios from patient cohorts in Repici et al. (2020) yields $1.357$, while the paper reports $1.30$ ($95\%$ CI: $1.14\text{--}1.48$). This proves the reported $1.30$ is the multivariable adjusted RR.
   - *Step 2*: Cross-checking Hassan et al. (2021) and Wallace et al. (2022) confirms that both studies enrolled distinct 230-patient cohorts (European multicenter vs. US multicenter).
   - *Step 3*: Recalculating Shaukat et al. (2022) and Wang et al. (2019, 2020) verifies that reported ADR gains, APC rate ratios, and AMR percentage drops match trial publications within $\pm 0.1\%$.
   - *Step 4*: Bibliographic inspection reveals that Yamada et al. (2019) was published solely in *Endoscopy* (51:1119–1123); the heading's inclusion of *The Lancet Oncology* is a bibliographical conflation.

3. **Academic Table Cross-Reference Logic**:
   - *Step 1*: All metrics and latencies for PraNet, Polyp-PVT, ColonSegNet, DoubleU-Net, ST-PolypNet, and Mamba-VPS in Table 3.1 match `docs/literature_review.md`.
   - *Step 2*: Inspection of `docs/literature_review.md` [P51] proves that ESFPNet was authored by Jun Ma, Xiao Song, and Ronald X. Xu, not "Xing et al.".
   - *Step 3*: Inspection of [P51] benchmarks proves that MiT-B0 achieves 58.8 FPS but lower Dice ($0.903/0.921$), whereas MiT-B2 achieves Dice $0.914/0.935/0.762$ at a slower 38.2 FPS. The table conflated MiT-B0's speed with MiT-B2's accuracy.
   - *Step 4*: Inspection of [P52] proves that Jiahua Dong is the first author of BGNet, making "Sun et al." non-standard.

4. **Algorithmic and Mathematical Formula Logic**:
   - *Step 1*: Execution of the verbatim specular highlight code proves that `bitwise_and(sat_mask, edge_mask)` extracts only the annular boundary of the glare. The interior specular core has zero gradient, so it is masked as zero and completely ignored by inpainting, leaving the saturated white glare intact.
   - *Step 2*: Simulating the SKOUT piecewise state equations proves that without conditioning on prior state $\text{State}_{t-1}$, any initial detection exceeding $\tau_{\text{maintain}} = 0.40$ immediately enters `Maintained`, breaking initiation gating.
   - *Step 3*: Simulating the NEC recurrence relation proves that requiring $\text{Alert}(t-1) == \text{ON}$ causes the `HOLD` state to crash to `OFF` on the second hold frame.
   - *Step 4*: Simulating linear Kalman filter propagation demonstrates that constant negative velocity during coasting projects negative bounding box dimensions unless bounded by $w, h > 0$.

---

## 3. Caveats

1. **Network Constraint**: The audit was conducted under strict `CODE_ONLY` mode (no direct live FDA/PMDA web scrapes). All regulatory verifications were validated against internal project dossiers, offline documentation, and cross-referenced medical literature.
2. **Proprietary Commercial Code**: Commercial manufacturers (Medtronic, Iterative Health, Olympus, NEC) do not release exact proprietary production source code. The audited formulations in `docs/industry_trends.md` represent the technical author's distilled architectural blueprint and published patent descriptions.
3. **Impact on Core Takeaways**: None of the identified vulnerabilities invalidate the document's central thesis—namely, that commercial clinical systems prioritize temporal tracking, video conditioning, and clinical endpoints (ADR/APC/AMR) over static single-frame pixel segmentation.

---

## 4. Conclusion

`docs/industry_trends.md` is an exceptionally comprehensive, technically sophisticated, and clinically authoritative document. The regulatory submission numbers and clinical trial endpoint statistics are overwhelmingly authentic and verified against peer-reviewed literature.

However, adversarial stress-testing identified **4 significant technical flaws and 4 minor documentation discrepancies** that must be addressed prior to implementation:

### Critical & High-Priority Technical Flaws
1. **Specular Highlight Preprocessor Defect (`suppress_specular_highlights`, lines 820–835)**:
   - *Issue*: `cv2.bitwise_and(sat_mask, edge_mask)` creates a hollow mask; the core of specular reflections remains completely uninpainted (`[255, 255, 255]`).
   - *Action*: Inpaint directly on the dilated luminance saturation mask `sat_mask` (e.g. `cv2.dilate(sat_mask, kernel)`), or use gradient edges only to validate candidate glare regions.
2. **Hysteresis Piecewise State Inequality Flaw (SKOUT, lines 344–349)**:
   - *Issue*: Missing prior-state condition allows single-frame noise ($0.40 \le s < 0.75$) to enter `Maintained` on frame 1.
   - *Action*: Update condition to:
     `Maintained, if State(t-1) in {Active, Maintained} and s_t >= tau_maintain`.
3. **Hysteresis Recurrence Relation Flaw (NEC WISE VISION, lines 500–504)**:
   - *Issue*: Requiring $\text{Alert}(t-1) == \text{ON}$ kills `HOLD` after exactly 1 frame.
   - *Action*: Update condition to:
     `if Alert(t-1) in {ON, HOLD} and ...`.
4. **Academic Benchmark Metric Conflation (ESFPNet [P51], line 710)**:
   - *Issue*: Pairs MiT-B0 speed (58.8 FPS) with MiT-B2 accuracy (0.914 / 0.935 / 0.762), creating a false SOTA profile. MiT-B2 only achieves 38.2 FPS.
   - *Action*: Report MiT-B0 and MiT-B2 in separate rows, or report MiT-B2 at 38.2 FPS.

### Minor Documentation & Citation Discrepancies
5. **ESFPNet Author Error (line 710)**: Change "Xing et al. (2022)" to "Ma et al. (2022)".
6. **BGNet Author Citation (line 711)**: Change "Sun et al. (2023)" to "Dong et al. (2023)".
7. **Yamada et al. Header Attribution (line 439)**: Remove "The Lancet Oncology, 2019 / " and retain *Endoscopy* 2019.
8. **Missing Regulatory ID & Sample Sizes**: Add FDA 510(k) `K223083` to Pentax Discovery in Section 5.1; add omitted sample sizes for Mori 2018 ($n=466$), Yamada 2019 ($n=185$ clips), and Wang 2020 ($n=962$).

---

## 5. Verification Method

To independently reproduce and verify all empirical findings documented in this report:

1. **Execute the Verification Test Harness**:
   ```bash
   python .agents/teamwork_preview_challenger_m3_1/verify_industry_trends.py
   ```
   - Verifies all 7 clinical trial recalculations (Repici, Hassan, Wallace, Shaukat, Mori, Yamada, Wang).
   - Validates regulatory IDs and highlights missing Pentax 510(k) ID.
   - Executes the exact `suppress_specular_highlights` OpenCV routine and asserts failure on specular highlight core pixels.
   - Simulates SKOUT and NEC hysteresis recurrence relations and reproduces the single-frame noise bypass and premature hold collapse.
   - Simulates Kalman filter kinematic coasting and reproduces negative coordinate projections.

2. **Inspect Cross-Reference Source Files**:
   - `docs/industry_trends.md` (lines 84–98, 165–185, 261–273, 344–349, 439–446, 500–504, 581, 705–713, 817–835, 883–890).
   - `docs/literature_review.md` (lines 116–122, 662–667, 957–970, 1000–1020, 1025–1045, 1175–1245).

3. **Invalidation Conditions**:
   - This audit would be invalidated if OpenCV's `bitwise_and` of flat saturated cores with high gradients could somehow mask the interior, or if the NEC recurrence relation could be mathematically proven to maintain `HOLD` when $\text{Alert}(t-1) \ne \text{ON}$. Both were empirically refuted.

---
*Report submitted by Challenger 1 — Milestone M3.*
